Evidera
Lalith Kumar Mittal is an experienced professional in health economics and outcomes research, currently serving as Team Lead for India at Evidera since August 2021, overseeing evidence synthesis, modeling, and communications projects. Prior to this role, Lalith held multiple positions at Eli Lilly and Company, including Senior Associate Manager in Value, Evidence and Outcomes, where responsibilities included coordinating the publication of scientific data and facilitating clinical trial development. Additional experience includes working as an Analyst at Kinapse, focusing on systematic literature reviews and health technology appraisals, as well as an intern at UnitedHealth Group, where Lalith contributed to literature reviews and HTA submissions. Lalith holds a Master's in Pharmacy from Manipal Academy of Higher Education, a Post Graduate Diploma in Intellectual Property Rights and Law from the National Law School of India University, and a Bachelor's in Pharmacy from Rajiv Gandhi University of Health Sciences.
This person is not in any offices
Evidera
1 followers
Evidera is a business within Pharmaceutical Product Development, LLC, (PPD) a leading global contract research organization (CRO), and is the preeminent provider of evidence-based solutions to demonstrate the real-world effectiveness, safety, and value of biopharmaceutical and biotechnology products from early development through loss of exclusivity. We provide integrated scientific expertise and global operational capabilities to help you generate the evidence needed to optimize the market access and commercial potential of your products. Evidera was acquired by PPD in 2016 and originally created in 2013 as an independent company under the ownership of Symphony Technology Group following the acquisition of long-standing health economics, outcomes research, market access, epidemiology, and data analytics practices from United BioSource Corporation (UBC). Evidera has over 30 years of leadership and experience and its legacy brands include MEDTAP, Caro Research, Abt Bio-Pharmaceutical Solutions, MetaWorks, Total Healthcare Group, and Archimedes.